Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
Want to see ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
$120.16
-$0.09(-1.29%)
At close: 4:00 PM EST
$120.16
-$0.09(-1.29%)
Day’s Range― - ―
52-Week Range$5.59 - $148.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)932.94K
Market Cap
$9.72B
Enterprise Value$7.91B
Total Cash (Recent Filing)$530.16M
Total Debt (Recent Filing)$32.08M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Sep 14, 2026EPS Estimate
-2.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding79,694,534
10 Day Avg. Volume950,950
30 Day Avg. Volume932,938
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-75.21
Forecast
1Y Price Target
$152.25Price Target Upside26.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$2.95M
Bulls Say, Bears Say
Bulls Say
Crohn's Disease Expansion PotentialPositive induction data in Crohn's disease combined with preclinical anti‑fibrotic effects suggest the drug could address both inflammation and fibrosis, expanding its market opportunity beyond ulcerative colitis.
Differentiated Clinical ProfileStrong induction efficacy, a benign safety profile, and convenient once‑daily oral dosing position the drug as a differentiated treatment that may attract prescribers seeking effective, easy‑to‑manage options.
Phase 3 Maintenance EfficacyPhase 3 maintenance results could determine whether the drug sustains remission versus placebo and approved therapies, making the readout a pivotal clinical and commercial inflection point.
Bears Say
Financing And Cash RunwayA limited cash runway coupled with a high cash burn could require additional financing before commercialization, increasing the risk of shareholder dilution and execution delays.
Leadership And Execution RiskSignificant leadership turnover and gaps in commercial and manufacturing expertise raise concerns about the company's ability to execute a smooth regulatory approval and market launch.
Valuation And Market VolatilityReliance on acquisition speculation combined with low trading volume increases valuation uncertainty and could amplify stock volatility if a deal fails to materialize or clinical maintenance data disappoint.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $5.59 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $9.72B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Sep 14, 2026 which is in 114 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -2.22.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 79,694,534 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$152.25 (26.71% Upside)
$152.25 (26.71% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Bullish
Bullish news 79%
Bearish news 25%
Bearish news 25%
Company Description
Abivax SA Sponsored ADR
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$152.25
▲(26.71% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
―
Insiders
6.14% Mutual Funds
40.25% Other Institutional Investors
52.82% Public Companies and Individual Investors